Search

Your search keyword '"Bipolar disorder -- Drug therapy"' showing total 1,530 results
Start Over Descriptor "Bipolar disorder -- Drug therapy"
1,530 results on '"Bipolar disorder -- Drug therapy"'

1. Demystifying Lithium Therapy--A Primer for Clinicians: Renal Issues

Author

Meyer, Jonathan M.

Subjects
Bipolar disorder -- Drug therapy, Patient compliance -- Health aspects, Type 2 diabetes -- Drug therapy, Evidence-based medicine -- Health aspects, Health, Psychology and mental health
Abstract

(This is the first part of a discussion on lithium. The second part will appear in a subsequent issue--Ed.) Lithium remains underused for the treatment of patients with a history [...]

Published
2024

2. NRx Pharma files initial section of NDA to US FDA for NRX-100 to treat suicidal depression

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Suicidal behavior -- Drug therapy, Depression, Mental -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the US Food & [...]

Published
2024

3. Researchers at Institute for Cancer Research and Treatment (IRCCS) San Raffaele Scientific Institute Release New Data on Personalized Medicine [Inflammatory Mediators in Major Depression and Bipolar Disorder (Russian Translation)]

Subjects
Bipolar disorder -- Drug therapy, Oncology, Experimental -- Reports, Major depressive disorder -- Drug therapy, Translating and interpreting -- Reports, Cancer -- Drug therapy -- Research, Physical fitness -- Reports, Health
Abstract

2024 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on personalized medicine. According to news originating from [...]

Published
2024

4. University College London (UCL) Researchers Further Understanding of Bipolar Disorders (Predicting maintenance lithium response for bipolar disorder from electronic health records-a retrospective study)

Subjects
Bipolar disorder -- Drug therapy, Medical research, Medicine, Experimental, Medical records, Antipsychotic drugs, Electronic records, Physical fitness, Health
Abstract

2024 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on bipolar disorders is now available. According to news [...]

Published
2024

5. Epilepsy medication affected Sophie's pregnancies. Should Australia adopt tougher guidelines? Exclusive: FoI documents show Advisory Committee on Medicines considered tightening prescribing requirements for sodium valproate -- but chose not toGet our breaking news email, free app or daily news podcast; Exclusive: FoI documents show Advisory Committee on Medicines considered tightening prescribing requirements for sodium valproate -- but chose not toGet our breaking news email, free app or daily news podcast

Subjects
Podcasting, Bipolar disorder -- Drug therapy, Electronic mail systems, Pregnancy, Birth defects -- Drug therapy, Prescription writing, Drugs, Pregnant women -- Drug therapy, Epilepsy -- Drug therapy, E-mail, News, opinion and commentary
Abstract

Byline: Natasha May Health reporter More than 100 pregnant women have been exposed to medication for epilepsy and bipolar disorder which carries a high risk of birth defects, as the [...]

Published
2024

7. University Hospitals Cleveland Medical Center Researcher Updates Understanding of Bipolar Disorders (Role of Electroconvulsive Therapy, Ketamine Infusion, and Deep Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar ...)

Subjects
Bipolar disorder -- Drug therapy, Medical research, Medicine, Experimental, Ketamine, Medical centers, Physical fitness, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on bipolar disorders are presented in a new report. According [...]

Published
2024

8. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Suicidal behavior -- Drug therapy, Ketamine, Depression, Mental -- Drug therapy, General interest, News, opinion and commentary
Abstract

WILMINGTON, Del: NRx Pharmaceuticals, Inc. has issued the following news release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx', the 'Company'), a clinical-stage biopharmaceutical company, today announced the transmission of first section [...]

Published
2024

9. Bipolar treatment: Are bipolar I and bipolar II treated differently?

Subjects
Bipolar disorder -- Drug therapy, Antidepressants, Asenapine, Psychotherapy, Lamotrigine, Mania -- Drug therapy, Health
Abstract

Answer Section Treatment for bipolar disorder, formerly called manic-depression, generally involves medications and forms of psychotherapy -- whether you have bipolar I or bipolar II. Bipolar II disorder is not [...]

Published
2024

10. Bipolar medications and weight gain

Subjects
Bipolar disorder -- Drug therapy, Antidepressants, Asenapine, Lithium carbonate, Drugs, Valproic acid, Divalproex, Lamotrigine, Health
Abstract

Answer Section Bipolar disorder can be treated with a number of medications. Some of these medications can increase your appetite or cause changes in metabolism leading to weight gain. Whether [...]

Published
2024

11. Lithium (generic): Eskalith, Eskalith CR, Lithobid (brand)

Subjects
Lithium, Bipolar disorder -- Drug therapy, Heart diseases -- Drug therapy, Heart beat, Lithium carbonate, Metronidazole, Hydrochlorothiazide, Pharmaceuticals and cosmetics industries, Health, Psychology and mental health, Eskalith CR (Medication), Lithobid (Medication)
Abstract

Classification: Mood stabilizer. Common usage: Lithium is indicated for the treatment of bipolar disorder (manic depression) in adults and in children aged 12 and older. The safety and effectiveness of [...]

Published
2024

12. Securing the Future of Lithium Research

Author

Mendelsohn, Alex and Aftab, Awais

Subjects
Bipolar disorder -- Drug therapy, Health, Psychology and mental health
Abstract

If I asked you to meet me at a restaurant but never mentioned a time for us to meet, it would be a useless invitation. A place without a time [...]

Published
2024

13. Drug supply crisis affects half a million patients with ADHD and mental illness

Subjects
Bipolar disorder -- Drug therapy, Schizophrenia -- Drug therapy, Attention-deficit hyperactivity disorder -- Drug therapy, General interest, News, opinion and commentary
Abstract

More than half a million patients face shortages of vital medications as Britain is hit by a crisis in the supply of drugs, The Independent has been told. The NHS [...]

Published
2024

14. Vanda Pharma receives US FDA approval for Fanapt for acute treatment of bipolar i disorder

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Iloperidone, Drug approval, Pharmaceuticals and cosmetics industries, Fanapt (Medication)
Abstract

Vanda Pharmaceuticals Inc. (Vanda), a leading global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Fanapt (iloperidone) tablets for the acute treatment of manic or [...]

Published
2024

15. Fanapt Approval Expanded to Include Treatment of Bipolar I Disorder

Author

Park, Brian

Subjects
Bipolar disorder -- Drug therapy, Iloperidone, Health
Abstract

The Food and Drug Administration (FDA) has expanded the approval of Fanapt[sup.®] (iloperidone) to include the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. [...]

Published
2024

16. Vanda Pharmaceuticals' Fanapt receives FDA approval

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Drug approval, Antipsychotic drugs, Business, News, opinion and commentary, Fanapt (Medication)
Abstract

Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Fanapt tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. [...]

Published
2024

17. Data on Bipolar Disorders Detailed by Researchers at University of Barcelona (Meta-analysis of the Effects of Adjuvant Drugs In Co-occurring Bipolar and Substance Use Disorder)

Subjects
Bipolar disorder -- Drug therapy, Medical research -- Analysis -- Reports, Medicine, Experimental -- Analysis -- Reports, Mental health -- Reports -- Analysis, Substance abuse -- Drug therapy, Health, Psychology and mental health, University of Barcelona -- Reports
Abstract

2024 DEC 16 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Investigators publish new report on Mental Health Diseases and Conditions - Bipolar Disorders. [...]

Published
2024

18. Data from McLean Hospital Provide New Insights into Bipolar Disorders (Responses to clinical treatment of bipolar versus unipolar depressive episodes in women versus men)

Subjects
Bipolar disorder -- Drug therapy, Medical research -- Psychological aspects, Medicine, Experimental -- Psychological aspects, Mental health -- Psychological aspects, Health, Psychology and mental health, McLean Hospital
Abstract

2024 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Investigators discuss new findings in bipolar disorders. According to news reporting from Belmont, [...]

Published
2024

21. Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Subjects
Bipolar disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, Clinical trials, Post-traumatic stress disorder -- Drug therapy, General interest, News, opinion and commentary
Abstract

ATLANTA: ALZAMEND NEURO, INC. has issued the following news release: Alzamend Neuro, Inc. (Nasdaq: ALZN) ('Alzamend'), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's [...]

Published
2024

22. Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Subjects
Bipolar disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, Clinical trials, Post-traumatic stress disorder -- Drug therapy, Business, Business, international
Abstract

* Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee * Identified dose is unlikely to [...]

Published
2024

23. Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Subjects
Teva Pharmaceutical Industries Ltd., Bipolar disorder -- Drug therapy, Movement disorders -- Drug therapy, Schizophrenia -- Drug therapy, Drugs, Tardive dyskinesia -- Drug therapy, Antipsychotic drugs, Pharmaceutical industry, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 - [...]

Published
2024

24. BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Subjects
Bipolar disorder -- Drug therapy, Dexmedetomidine, Drug approval, Clinical trials, Banking, finance and accounting industries, Business, Igalmi (Medication)
Abstract

E stimated 23 million annual agitation episodes in the at-home setting [sup. 1-3 ] No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders [...]

Published
2024

25. Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Subjects
United States. Food and Drug Administration, Brain -- Health aspects, Bipolar disorder -- Drug therapy, Lithium carbonate -- Product development, Clinical trials -- Health aspects, Post-traumatic stress disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, College teachers -- Health aspects, Cooperative agreement for product development, Business, Business, international, Harvard University, Massachusetts General Hospital
Abstract

* Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study * Head-to-head study of AL001 versus a marketed lithium carbonate product will [...]

Published
2024

26. Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Subjects
United States. Food and Drug Administration, Brain -- Health aspects, Bipolar disorder -- Drug therapy, Major depressive disorder -- Drug therapy, Lithium carbonate -- Product development, Clinical trials -- Health aspects, Post-traumatic stress disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, College teachers -- Health aspects, Business, Business, international, Harvard University, Massachusetts General Hospital
Abstract

* Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study * Head-to-head study of AL001 versus a marketed lithium carbonate product will [...]

Published
2024

27. Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Subjects
Brain -- Health aspects, Bipolar disorder -- Drug therapy, Lithium carbonate -- Product development, Clinical trials -- Health aspects, Post-traumatic stress disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, College teachers -- Health aspects, Business, Business, international, Harvard University, Massachusetts General Hospital
Abstract

* Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study * Head-to-head study of AL001 versus a marketed lithium carbonate product will [...]

Published
2024

28. Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer's Disease

Subjects
Brain -- Health aspects, Bipolar disorder -- Drug therapy, Diseases -- Drug therapy -- Georgia, Lithium carbonate -- Product development, Clinical trials -- Health aspects, Post-traumatic stress disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, College teachers -- Health aspects, Business, Business, international, Harvard University, Massachusetts General Hospital
Abstract

* Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study * Head-to-head study of AL001 versus a marketed lithium carbonate product will [...]

Published
2024

29. Approval

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Iloperidone, Drug approval, Clinical trials, Pharmaceuticals and cosmetics industries, Health, Psychology and mental health, Fanapt (Medication)
Abstract

The Food and Drug Administration (FDA) on April 2 announced the approval of iloperidone for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. [...]

Published
2024

30. The ethical quagmire of a fetus-harming epilepsy drug

Subjects
Bipolar disorder -- Drug therapy, Seizures (Medicine) -- Drug therapy, Drugs -- Ethical aspects, Anticonvulsants -- Ethical aspects, Pregnant women -- Drug therapy, Epilepsy -- Drug therapy, Business, Economics, Business, international
Abstract

WHEN HANNAH MULCAHY was 14 she had what she calls 'the big, bad one': the kind of seizure everyone imagines when they think of epilepsy. But her doctors hesitated to [...]

Published
2024

31. Polytechnic University of Marche Researchers Illuminate Research in Bipolar Disorders [The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review]

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Medical research, Medicine, Experimental, Technical institutes, Schizophrenia -- Drug therapy, Drug approval, Physical fitness, Health
Abstract

2024 JAN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on bipolar disorders is now available. According to news [...]

Published
2024

32. First Hospital of Jilin University Researchers Provide New Insights into Alzheimer Disease (Molecular mechanisms and therapeutic potential of lithium in Alzheimer's disease: repurposing an old class of drugs)

Subjects
Bipolar disorder -- Drug therapy, Medical research, Medicine, Experimental, Diseases -- Drug therapy -- China, Alzheimer's disease -- Drug therapy, Health
Abstract

2024 AUG 2 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Alzheimer disease are presented in a new report. According to [...]

Published
2024

35. New Type of Brain Stimulation Could Shorten Treatment Time for Bipolar Disorder

Subjects
Bipolar disorder -- Drug therapy, Medical research -- Reports, Medicine, Experimental -- Reports, Drug approval -- Reports, Health
Abstract

Byline: Dennis Thompson HealthDay Reporter THURSDAY, July 11, 2024 (HealthDay News) -- Powerful magnetic stimulation can help treat people with bipolar disorder, according to results from a small trial. The [...]

Published
2024

37. NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Depression, Mental -- Drug therapy, Drug approval, General interest, News, opinion and commentary
Abstract

RADNOR, Pa: NRx Pharmaceuticals, Inc has issued the following press release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', the 'Company'), a clinical-stage biopharmaceutical company, today announced that advice from regulatory [...]

Published
2024

38. ASRI Announces Groundbreaking Discovery: Bifunctional 5-HT2A Antagonist and Sodium Channel Blocker Holds Promise for Bipolar Disorder Treatment

Subjects
Bipolar disorder -- Drug therapy, Medical colleges, Lamotrigine, Business, News, opinion and commentary, Stanford University, Medical College of Wisconsin
Abstract

LAFAYETTE, Calif., May 31, 2024 /PRNewswire/ -- The Alexander Shulgin Research Institute (ASRI) has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as [...]

Published
2024

39. NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

Subjects
Bipolar disorder -- Drug therapy, Suicidal behavior -- Drug therapy, Trade and professional associations, Antidepressants, General interest, News, opinion and commentary
Abstract

RADNOR, Pa: NRx Pharmaceuticals, Inc. has issued the following news release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', 'NRx', the 'Company'), a clinical stage pharmaceutical company, today announced presentation of [...]

Published
2024

40. NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b|3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

Subjects
Bipolar disorder -- Drug therapy, Suicidal behavior -- Drug therapy, Antidepressants, Clinical trials, Suicide, General interest, News, opinion and commentary
Abstract

RADNOR, Pa: NRx Pharmaceuticals has issued the following news release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', the 'Company'), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated [...]

Published
2024

42. Alzamend Neuro Gets FDA 'Study May Proceed' Notification for a Phase IIA Clinical Trial of AL001

Subjects
United States. Food and Drug Administration, Bipolar disorder -- Drug therapy, Drug approval, Clinical trials, Post-traumatic stress disorder -- Drug therapy, Arts and entertainment industries
Abstract

Alzamend Neuro, a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), reported [...]

Published
2023

43. Study Data from School of Medicine Provide New Insights into Obsessive-Compulsive Disorder (Comparison of Aripiprazole and Risperidone effectiveness in treating obsessive-compulsive disorder in patients with bipolar disorder: Double-blind, ...)

Subjects
Bipolar disorder -- Drug therapy, Aripiprazole -- Testing -- Complications and side effects, Obsessive-compulsive disorder -- Drug therapy, Risperidone -- Testing -- Complications and side effects, Health
Abstract

2023 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on obsessive-compulsive disorder have been published. According to news [...]

Published
2023

44. Uniwersytet Medyczny w Lublinie Researchers Further Understanding of Bipolar Disorders (Modafinil. Armodafinil. The use of eugeroics in assisting the treatment of depression, bipolar disorder, and schizophrenia. Benefits, drawbacks, and adverse ...)

Subjects
Bipolar disorder -- Drug therapy, Medical research -- Usage, Medicine, Experimental -- Usage, Nervous system agents -- Usage, Schizophrenia -- Drug therapy, Narcolepsy -- Drug therapy, Modafinil -- Usage, Physical fitness -- Usage, Armodafinil -- Usage, Health
Abstract

2023 SEP 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on bipolar disorders have been published. According to news [...]

Published
2023

45. Antipsychotic drugs overprescribed to people with Alzheimer’s, dementia living at home

Author

Fischer, Kristen

Subjects
Bipolar disorder -- Drug therapy, Alzheimer's disease -- Drug therapy, Schizophrenia -- Drug therapy, Drug approval, Antipsychotic drugs, Business, Health, Health care industry, Seniors
Abstract

People with Alzheimer’s disease and related dementias who receive home health are likely getting prescribed https://www.mcknights.com/news/clinical-news/dementia-diagnosis-offers-missed-opportunity-to-cut-meds-study-finds/ too often, according to a new study. The research was published Wednesday in the [...]

Published
2023

46. Study Results from University of California San Diego (UCSD) in the Area of Bipolar Disorders Reported (Focal Adhesion Is Associated With Lithium Response In Bipolar Disorder: Evidence From a Network-based Multi-omics Analysis)

Subjects
Bipolar disorder -- Drug therapy, Lithium -- Usage -- Physiological aspects, Molecular neurobiology -- Research, Psychiatric research, Cell adhesion -- Health aspects, Health
Abstract

2023 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Mental Health Diseases and Conditions - Bipolar Disorders is [...]

Published
2023

47. University of Manchester Researcher Provides New Insights into Bipolar Disorders (Maintenance Treatments of Lithium, Carbamazepine, and Adjunctive CBT in Bipolar Disorder: Review)

Subjects
Bipolar disorder -- Drug therapy, Medical research, Medicine, Experimental, Mental health, Carbamazepine, Physical fitness, Health, University of Manchester
Abstract

2023 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in bipolar disorders. According to news reporting from [...]

Published
2023

48. NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

Subjects
Bipolar disorder -- Drug therapy, Suicidal behavior -- Drug therapy, Medical research, Medicine, Experimental, Antidepressants -- Product development, Clinical trials, Business, News, opinion and commentary
Abstract

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to [...]

Published
2024

49. Response Pharmaceuticals' Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG)

Subjects
Bipolar disorder -- Drug therapy, Body weight, Schizophrenia -- Drug therapy, Mentally ill -- Drug therapy, Drugs, Antipsychotic drugs, Weight loss industry, General interest, News, opinion and commentary
Abstract

FALLS CHURCH: Response Pharmaceuticals, Inc., a clinical stage company focused on weight management and metabolic health in high-risk populations, announced positive topline results from its Phase 1b clinical trial evaluating [...]

Published
2024

50. BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Subjects
United States. Food and Drug Administration -- Evaluation -- Planning, Business plans, Bipolar disorder -- Drug therapy, Schizophrenia -- Drug therapy, Dexmedetomidine -- Evaluation, Drug approval, Business planning, Company business planning, Banking, finance and accounting industries, Business, Igalmi (Medication) -- Evaluation
Abstract

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results